ADMA Biologics

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906.
Type
Public
HQ
Ramsey, US
Founded
2004
Size (employees)
72 (est)+20%
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US

Key People at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman

ADMA Biologics Office Locations

ADMA Biologics has office in Ramsey
Ramsey, US

ADMA Biologics Metrics

ADMA Biologics Summary

Market capitalization

$63.7 M

Closing share price

$4.97
ADMA Biologics's current market capitalization is $63.7 M.

ADMA Biologics Financials

ADMA Biologics's revenue is $7.18 M in FY, 2015 which is 21.34% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$7.18 M$5.92 M$3.07 M

Revenue growth, %

21.3%92.8%

Gross profit

$2.87 M$2.17 M$1.04 M

Operating income

$-15.5 M$-16 M$-15 M

Operating expense total

$22.7 M$21.9 M$18.1 M

Net Income

$-18 M$-16.8 M$-15.5 M

Operating cash flow

$-6.76 M$-8.95 M$13.6 M

ADMA Biologics Market Value History

We estimate that ADMA Biologics's current employees are approximately 7% female and 93% male.

ADMA Biologics News

ADMA Biologics Company Life

You may also be interested in